Benjamin Hohl - 28 Dec 2023 Form 4 Insider Report for Enliven Therapeutics, Inc. (ELVN)

Role
Chief Financial Officer
Signature
/s/ Benjamin Hohl
Issuer symbol
ELVN
Transactions as of
28 Dec 2023
Net transactions value
-$148,889
Form type
4
Filing time
02 Jan 2024, 19:59:41 UTC
Previous filing
27 Dec 2023
Next filing
31 Jan 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ELVN Common Stock Options Exercise $6,118 +2,467 $2.48 2,467 28 Dec 2023 Direct F1
transaction ELVN Common Stock Sale $37,188 -2,467 -100% $15.07 0 28 Dec 2023 Direct F1, F2
transaction ELVN Common Stock Options Exercise $49.6 +20 $2.48 20 29 Dec 2023 Direct F1
transaction ELVN Common Stock Sale $300 -20 -100% $15.00 0 29 Dec 2023 Direct F1
transaction ELVN Common Stock Options Exercise $23,270 +9,383 $2.48 9,383 02 Jan 2024 Direct F1
transaction ELVN Common Stock Sale $140,839 -9,383 -100% $15.01 0 02 Jan 2024 Direct F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ELVN Employee Stock Option (right to buy) Options Exercise $0 -2,467 -0.95% $0.000000 258,523 28 Dec 2023 Common Stock 2,467 $2.48 Direct F1, F4
transaction ELVN Employee Stock Option (right to buy) Options Exercise $0 -20 -0.01% $0.000000 258,503 29 Dec 2023 Common Stock 20 $2.48 Direct F1, F4
transaction ELVN Employee Stock Option (right to buy) Options Exercise $0 -9,383 -3.6% $0.000000 249,120 02 Jan 2024 Common Stock 9,383 $2.48 Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023.
F2 This transaction was executed in multiple trades at prices ranging from $15.00 to $15.27. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F3 This transaction was executed in multiple trades at prices ranging from $15.00 to $15.01. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F4 The option, originally for 262,120 shares, vested as to one-fourth of the shares vests on August 2, 2022, and the remainder of the shares vest in 36 equal monthly installments thereafter.